

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMERIGEN PHARMACEUTICALS LIMITED and  
ARGENTUM PHARMACEUTICALS LLC  
Petitioners,

v.

JANSSEN ONCOLOGY, INC.  
Patent Owner.

---

Case IPR2016-00286<sup>1</sup>  
Patent 8,822,438 B2

---

**DECLARATION OF  
CHRISTOPHER A. VELLTURO, PH.D.  
IN SUPPORT OF PATENT OWNER RESPONSE**

---

<sup>1</sup> I understand case IPR2016-01317 has been joined with this proceeding.

## Table of Contents

	Page(s)
I. INTRODUCTION AND SUMMARY.....	1
A. Qualifications and Experience .....	2
B. Evidence Considered.....	3
C. Summary of Opinions .....	3
II. BACKGROUND .....	6
A. Prostate Cancer.....	6
B. Demand for mCRPC treatment .....	7
C. ZYTIGA® .....	9
D. The Patent-at-Issue .....	10
III. CONSIDERATION OF MCDUFF DECLARATION.....	10
A. Overview of Dr. McDuff’s Contentions .....	11
B. The Barrie Patent as a Purported “Blocking Patent” Does Not Invalidate a Commercial Success Assessment.....	13
1. Overview .....	13
2. Development and License Attempts of Abiraterone Acetate.....	15
C. Dr. McDuff’s Analysis Concerning the Relevance of ZYTIGA®’s “Unexpected Commercial Success” Is Incorrect .....	16
D. Dr. McDuff’s Mischaracterization of Marketplace Success .....	17
IV. AFFIRMATIVE ASSESSMENT.....	19
A. Evaluation of Marketplace Success .....	19
B. ZYTIGA®’s Commercial Success Is Due in Significant Part to	

the Claims of the '438 Patent .....	22
1. The '438 Patent Covers the Only FDA-Approved Use of ZYTIGA® .....	23
2. Physicians Value ZYTIGA® – The Combination of Abiraterone Acetate and Prednisone – for its Therapeutic Survival Benefit .....	23
3. ZYTIGA®'s Commercial Success Is Not Attributable to Excessive Marketing Spend Levels .....	26
4. ZYTIGA®'s Commercial Success Is Not Due to Aggressively Low Pricing.....	28
V. CONCLUSION.....	29

I, Christopher A. Velluro, hereby declare and state as follows:

## **I. INTRODUCTION AND SUMMARY**

1. I have been retained as a consultant on behalf of Janssen Oncology, Inc. (“Janssen”), the patent owner in the present proceeding. I understand that the petition names Amerigen Pharmaceuticals Limited (“Amerigen”) and Argentum Pharmaceuticals LLC (“Argentum”) (collectively, “petitioners”). I have no financial interest in, or affiliation with, the petitioners or the patent owner. Quantitative Economic Solutions, LLC, a consulting firm of which I am the founder and president, is being compensated for my work at my usual and customary hourly consulting rate of \$850.<sup>2</sup> QES’s compensation is not dependent upon the outcome of, or my testimony in, the present *inter partes* review or any litigation proceedings.

2. I have been asked to evaluate the analyses and conclusions put forth on behalf of the petitioners by Dr. Deforest McDuff in his declaration (“the McDuff Declaration”).<sup>3</sup> I have also been asked to independently evaluate the commercial

---

<sup>2</sup> QES is also compensated for the time spent on this matter by persons working at my direction. Those rates are generally lower than my hourly rate.

<sup>3</sup> Declaration of DeForest McDuff, Ph.D., December 4, 2015 (Ex. 1017).

success of the combination therapy of abiraterone acetate and prednisone – marketed by Janssen as ZYTIGA®<sup>4</sup> – and the extent to which ZYTIGA®’s commercial success is causally linked to the patent claims in U.S. Patent No. 8,822,438 B2 (“the ’438 patent” or the “Patent-at-Issue”).

**A. Qualifications and Experience**

3. My qualifications and experience relevant to the issues in this proceeding are summarized below. My *curriculum vitae* is submitted herewith as Exhibit 2040.

4. I am the founder and president of Quantitative Economic Solutions, LLC, a microeconomic consulting firm. I received a Doctor of Philosophy degree (Ph.D.) in Economics from the Massachusetts Institute of Technology in Cambridge, Massachusetts in 1989. My fields of specialization include industrial organization and econometrics.

---

<sup>4</sup> As used herein, unless otherwise stated, the term “ZYTIGA®” refers to ZYTIGA® therapy, *i.e.*, abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. (*See Ex. 1065*).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.